Alpenglow Biosciences, a Seattle-based biotech startup founded in 2018, has recently received a $2 million research grant from the National Institute of Health and a $1 million investment to further develop its 3D spatial biology imaging technology platform. Jonathan Liu, one of the company’s co-founders and a UW professor, also secured a contract worth up to $21 million to develop technology for precision tumor removal as part of the Biden Administration’s Cancer Moonshot initiative.
Led by CEO Nicholas Reder, Alpenglow Biosciences was formerly known as Lightspeed Microscopy before rebranding. The company’s team of 20 employees is dedicated to advancing research in the field of biotechnology. The company’s investors include Alexandria, Dynamk Capital, First In Ventures, Hamamatsu, Mayo Clinic, and WRF Capital, highlighting the strong support and interest in Alpenglow’s innovative technologies.
The $2 million grant from the NIH will allow Alpenglow to continue its research and development efforts in 3D spatial biology imaging technology, which has the potential to revolutionize the way biological systems are studied and understood. The $1 million investment will further support the company’s platform development, ensuring that their technology remains at the forefront of the biotech industry.
Jonathan Liu’s success in securing a contract worth up to $21 million for precision tumor removal technology showcases the potential impact of Alpenglow’s innovative approach to biotechnology. As part of the Cancer Moonshot initiative, this contract will enable the company to contribute to advancements in cancer treatment and patient care, further solidifying their position as leaders in the field.
With a strong team of 20 employees, including experienced professionals and researchers, Alpenglow Biosciences is well-positioned to continue its trajectory of success. The company’s dedication to innovation and collaboration, as evidenced by their partnerships with leading institutions and investors, underscores their commitment to advancing biotechnology research and development.
Overall, the recent achievements of Alpenglow Biosciences demonstrate the company’s potential to make significant contributions to the field of biotechnology. With the support of the NIH grant, investment, and Jonathan Liu’s contract for precision tumor removal technology, the company is poised to further expand its impact and drive advancements in 3D spatial biology imaging technology and cancer research.
